z-logo
open-access-imgOpen Access
The landscape of antibody binding in SARS-CoV-2 infection
Author(s) -
Anna S. Heffron,
Sean McIlwain,
Maya F. Amjadi,
David Baker,
Saniya Khullar,
Tammy Armbrust,
Peter Halfmann,
Yoshihiro Kawaoka,
Ajay K. Sethi,
Ann C. Palmenberg,
Miriam A. Shelef,
David H. O’Connor,
Irene M. Ong
Publication year - 2021
Publication title -
plos biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.127
H-Index - 271
eISSN - 1545-7885
pISSN - 1544-9173
DOI - 10.1371/journal.pbio.3001265
Subject(s) - epitope , biology , proteome , virology , antibody , coronavirus , epitope mapping , population , immunology , covid-19 , genetics , medicine , disease , environmental health , pathology , infectious disease (medical specialty)
The search for potential antibody-based diagnostics, vaccines, and therapeutics for pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has focused almost exclusively on the spike (S) and nucleocapsid (N) proteins. Coronavirus membrane (M), ORF3a, and ORF8 proteins are humoral immunogens in other coronaviruses (CoVs) but remain largely uninvestigated for SARS-CoV-2. Here, we use ultradense peptide microarray mapping to show that SARS-CoV-2 infection induces robust antibody responses to epitopes throughout the SARS-CoV-2 proteome, particularly in M, in which 1 epitope achieved excellent diagnostic accuracy. We map 79 B cell epitopes throughout the SARS-CoV-2 proteome and demonstrate that antibodies that develop in response to SARS-CoV-2 infection bind homologous peptide sequences in the 6 other known human CoVs. We also confirm reactivity against 4 of our top-ranking epitopes by enzyme-linked immunosorbent assay (ELISA). Illness severity correlated with increased reactivity to 9 SARS-CoV-2 epitopes in S, M, N, and ORF3a in our population. Our results demonstrate previously unknown, highly reactive B cell epitopes throughout the full proteome of SARS-CoV-2 and other CoV proteins.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here